Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Coleman Baker, Yang Liu, Jing Zou, Antonio Muruato, Xuping Xie & Pei-Yong Shi. (2020) Identifying optimal capsid duplication length for the stability of reporter flaviviruses. Emerging Microbes & Infections 9:1, pages 2256-2265.
Read now
Read now
Laura Lazo, Iris Valdes, Gerardo Guillén, Lisset Hermida & Lázaro Gil. (2019) Aiming at the heart: the capsid protein of dengue virus as a vaccine candidate. Expert Review of Vaccines 18:2, pages 161-173.
Read now
Read now
Sandra Bos, Gilles Gadea & Philippe Despres. (2018) Dengue: a growing threat requiring vaccine development for disease prevention. Pathogens and Global Health 112:6, pages 294-305.
Read now
Read now
Laurent Coudeville, Nicolas Baurin & Gustavo Olivera-Botello. (2018) Assessment of benefits and risks associated with dengue vaccination at the individual and population levels: a dynamic modeling approach. Expert Review of Vaccines 17:8, pages 753-763.
Read now
Read now
Articles from other publishers (37)
Geraldine Nadya Putri, Chandra Sekhar Gudla, Mayas Singh, Chin Huan Ng, Fakhriedzwan Fitri Haji Idris, Yukei Oo, Jasmine Hwee Yee Tan, Joel Feng Jie Wong, Justin Jang Hann Chu, Vignesh Selvam, Siva Shanmugam Selvaraj, Radha Krishan Shandil, Shridhar Narayanan & Sylvie Alonso. (2023) Expanding the anti-flaviviral arsenal: Discovery of a baicalein-derived Compound with potent activity against DENV and ZIKV.. Antiviral Research 220, pages 105739.
Crossref
Crossref
Almonther Abdullah Hershan. (2023) Dengue Virus: Molecular Biology and Recent Developments in Control Strategies, Prevention, Management, and Therapeutics. Journal of Pharmacology and Pharmacotherapeutics 14:2, pages 107-124.
Crossref
Crossref
Lorena Zuzic, Jan K Marzinek, Ganesh S Anand, Jim Warwicker & Peter J Bond. (2023) A pH-dependent cluster of charges in a conserved cryptic pocket on flaviviral envelopes. eLife 12.
Crossref
Crossref
Yaning Gao, Wanbo Tai, Xinyi Wang, Shibo Jiang, Asim K. Debnath, Lanying Du & Shizhong Chen. (2022) A gossypol derivative effectively protects against Zika and dengue virus infection without toxicity. BMC Biology 20:1.
Crossref
Crossref
Luana E. Piccini, Viviana Castilla & Elsa B. Damonte. (2022) Inhibition of dengue virus infection by trifluoperazine. Archives of Virology 167:11, pages 2203-2212.
Crossref
Crossref
Li-Hsin Li, Laurens Liesenborghs, Lanjiao Wang, Marleen Lox, Michael Bright Yakass, Sander Jansen, Ana Lucia Rosales Rosas, Xin Zhang, Hendrik Jan Thibaut, Dirk Teuwen, Johan Neyts, Leen Delang & Kai Dallmeier. (2022) Biodistribution and environmental safety of a live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Molecular Therapy - Methods & Clinical Development 25, pages 215-224.
Crossref
Crossref
Sheikh Murtuja, Deepak Shilkar, Biswatrish Sarkar, Barij Nayan Sinha & Venkatesan Jayaprakash. (2022) A Critical Observation on the Design and Development of Reported
Peptide Inhibitors of DENV NS2B-NS3 Protease in the Last Two Decades. Mini-Reviews in Medicinal Chemistry 22:8, pages 1108-1130.
Crossref
Crossref
E. I. Kazachinskaia, D. V. Shanshin, D. N. Scherbakov & A. M. Shestopalov. (2022) Problematic questions in the development of specific prevention of dengue fever. Medical Immunology (Russia) 24:1, pages 19-30.
Crossref
Crossref
Laura A. VanBlargan, Pavle S. Milutinovic, Leslie Goo, Christina R. DeMaso, Anna P. Durbin, Stephen S. Whitehead, Theodore C. Pierson & Kimberly A. Dowd. (2021) Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera. Journal of Virology 95:23.
Crossref
Crossref
Sheikh Murtuja, Deepak Shilkar, Biswatrish Sarkar, Barij Nayan Sinha & Venkatesan Jayaprakash. (2021) A short survey of dengue protease inhibitor development in the past 6 years (2015–2020) with an emphasis on similarities between DENV and SARS-CoV-2 proteases. Bioorganic & Medicinal Chemistry 49, pages 116415.
Crossref
Crossref
L. M. Khantimirova, D. V. Gorenkov, S. G. Guseva, V. A. Merkulov & A. A. Soldatov. (2021) Approaches to quality control, preclinical and clinical studies of live recombinant viral vector vaccines. BIOpreparations. Prevention, Diagnosis, Treatment 21:4, pages 212-224.
Crossref
Crossref
Adewale Oluwaseun Fadaka, Nicole Remaliah Samantha Sibuyi, Darius Riziki Martin, Mediline Goboza, Ashwil Klein, Abram Madimabe Madiehe & Mervin Meyer. (2021) Immunoinformatics design of a novel epitope-based vaccine candidate against dengue virus. Scientific Reports 11:1.
Crossref
Crossref
Hemalatha Beesetti & Sathyamangalam Swaminathan. (2021) Adenovirus type 5 vectors encoding short hairpin RNAs targeting dengue virus 5’ non-translated region and capsid gene suppress pre-established dengue infection in cultured epithelial and myeloid cells. Virus Research 304, pages 198527.
Crossref
Crossref
Clairissa A. Hansen & Alan D. T. Barrett. (2021) The Present and Future of Yellow Fever Vaccines. Pharmaceuticals 14:9, pages 891.
Crossref
Crossref
Amanda E. Calvert, Kalanthe Horiuchi, Karen L. Boroughs, Yee T. Ong, Kimberly M. Anderson, Brad J. Biggerstaff, Mars Stone, Graham Simmons, Michael P. Busch & Claire Y.-H. Huang. (2021) The Specificity of the Persistent IgM Neutralizing Antibody Response in Zika Virus Infections among Individuals with Prior Dengue Virus Exposure. Journal of Clinical Microbiology 59:8.
Crossref
Crossref
Rong Zhao, Meiyue Wang, Jing Cao, Jing Shen, Xin Zhou, Deping Wang & Jimin Cao. (2021) Flavivirus: From Structure to Therapeutics Development. Life 11:7, pages 615.
Crossref
Crossref
Lorena Sanchez-Felipe, Thomas Vercruysse, Sapna Sharma, Ji Ma, Viktor Lemmens, Dominique Van Looveren, Mahadesh Prasad Arkalagud Javarappa, Robbert Boudewijns, Bert Malengier-Devlies, Laurens Liesenborghs, Suzanne J. F. Kaptein, Carolien De Keyzer, Lindsey Bervoets, Sarah Debaveye, Madina Rasulova, Laura Seldeslachts, Li-Hsin Li, Sander Jansen, Michael Bright Yakass, Babs E. Verstrepen, Kinga P. Böszörményi, Gwendoline Kiemenyi-Kayere, Nikki van Driel, Osbourne Quaye, Xin Zhang, Sebastiaan ter Horst, Niraj Mishra, Ward Deboutte, Jelle Matthijnssens, Lotte Coelmont, Corinne Vandermeulen, Elisabeth Heylen, Valentijn Vergote, Dominique Schols, Zhongde Wang, Willy Bogers, Thijs Kuiken, Ernst Verschoor, Christopher Cawthorne, Koen Van Laere, Ghislain Opdenakker, Greetje Vande Velde, Birgit Weynand, Dirk E. Teuwen, Patrick Matthys, Johan Neyts, Hendrik Jan Thibaut & Kai Dallmeier. (2020) A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Nature 590:7845, pages 320-325.
Crossref
Crossref
Sheikh Murtuja, Deepak Shilkar, Biswatrish Sarkar, Barij Nayan Sinha & Venkatesan Jayaprakash. 2021. Human Viruses: Diseases, Treatments and Vaccines. Human Viruses: Diseases, Treatments and Vaccines
93
120
.
Madhumati Sevvana & Richard J Kuhn. (2020) Mapping the diverse structural landscape of the flavivirus antibody repertoire. Current Opinion in Virology 45, pages 51-64.
Crossref
Crossref
Rahul Shukla, Hemalatha Beesetti, Julia A. Brown, Richa Ahuja, Viswanathan Ramasamy, Rajgokul K. Shanmugam, Ankur Poddar, Gaurav Batra, Florian Krammer, Jean K. Lim, Sachin Kale, Altaf A. Lal, Sathyamangalam Swaminathan & Navin Khanna. (2020) Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models. EBioMedicine 60, pages 102991.
Crossref
Crossref
Mareike Kubinski, Jana Beicht, Thomas Gerlach, Asisa Volz, Gerd Sutter & Guus F. Rimmelzwaan. (2020) Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise. Vaccines 8:3, pages 451.
Crossref
Crossref
Josilene Ramos Pinheiro-Michelsen, Rayane da Silva Oliveira Souza, Itana Vivian Rocha Santana, Patrícia de Souza da Silva, Erick Carvalho Mendez, Wilson Barros Luiz & Jaime Henrique Amorim. (2020) Anti-dengue Vaccines: From Development to Clinical Trials. Frontiers in Immunology 11.
Crossref
Crossref
Clemente DiazMichael KorenLeyi LinLuis J. MartinezKenneth H. EckelsMaribel CamposRichard G. JarmanRafael De La BarreraEdith Lepine, Irma FeboDavid W. Vaughn, Todd M. Wilson, Robert M. Paris, Alexander C. Schmidt & Stephen J. Thomas. (2020) Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study. The American Journal of Tropical Medicine and Hygiene 102:5, pages 951-954.
Crossref
Crossref
Stanley A Plotkin. (2020) Dengue Vaccine, A Double-Edged Sword. Journal of the Pediatric Infectious Diseases Society 9:2, pages 107-109.
Crossref
Crossref
Sheng-Qun Deng, Xian Yang, Yong Wei, Jia-Ting Chen, Xiao-Jun Wang & Hong-Juan Peng. (2020) A Review on Dengue Vaccine Development. Vaccines 8:1, pages 63.
Crossref
Crossref
Khadija Zahid, Sana Shakoor, Hina Afzal Sajid, Samia Afzal, Liaqat Ali, Iram Amin, Muhammad Shahid & Muhammad Idrees. (2020) Advancements in developing an effective and preventive dengue vaccine. Future Virology 15:2, pages 127-138.
Crossref
Crossref
Iris Valdés, Laura Lazo, Lisset Hermida, Gerardo Guillén & Lázaro Gil. (2019) Can Complementary Prime-Boost Immunization Strategies Be an Alternative and Promising Vaccine Approach Against Dengue Virus?. Frontiers in Immunology 10.
Crossref
Crossref
Satish N. Dighe, O'mezie Ekwudu, Kamal Dua, Dinesh Kumar Chellappan, Peter L. Katavic & Trudi A. Collet. (2019) Recent update on anti-dengue drug discovery. European Journal of Medicinal Chemistry 176, pages 431-455.
Crossref
Crossref
Anthony Fauci, Emily Erbelding, Stephen Whitehead, M. Cristina Cassetti, F. Gray Handley & Ranjan Gupta. (2019) Dengue vaccine clinical trials in India — An opportunity to inform the global response to a re-emerging disease challenge. International Journal of Infectious Diseases 84, pages S4-S6.
Crossref
Crossref
Mathieu Trauchessec, Olivier Lambert, Pierre Bonnafous, Yves Berard, Fabienne Barriere, Celine Huillet, Sergio Marco, Devika Sirohi, Victoria Hedrick, Richard Kuhn, Bruno Guy, Frederic Ronzon & Catherine Manin. (2019) Complementary use of mass spectrometry and cryo-electron microscopy to assess the maturity of live attenuated dengue vaccine viruses. Vaccine 37:27, pages 3580-3587.
Crossref
Crossref
Chloé Pasin, M. Elizabeth Halloran, Peter B. Gilbert, Edith Langevin, R. Leon Ochiai, Punnee Pitisuttithum, Maria Rosario Capeding, Gabriel Carrasquilla, Carina Frago, Margarita Cortés, Laurent Chambonneau & Zoe Moodie. (2018) Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease. PLOS ONE 13:12, pages e0207878.
Crossref
Crossref
Nagesh K. Tripathi & Ambuj Shrivastava. (2018) Recent Developments in Recombinant Protein–Based Dengue Vaccines. Frontiers in Immunology 9.
Crossref
Crossref
Satoru Watanabe, Jenny Guek-Hong Low & Subhash G. Vasudevan. (2018) Preclinical Antiviral Testing for Dengue Virus Infection in Mouse Models and Its Association with Clinical Studies. ACS Infectious Diseases 4:7, pages 1048-1057.
Crossref
Crossref
J.L. Arredondo-García, S.R. Hadinegoro, H. Reynales, M.N. Chua, D.M. Rivera Medina, T. Chotpitayasunondh, N.H. Tran, C.C. Deseda, D.N. Wirawan, M. Cortés Supelano, C. Frago, E. Langevin, D. Coronel, T. Laot, A.P. Perroud, L. Sanchez, M. Bonaparte, K. Limkittikul, D. Chansinghakul, S. Gailhardou, F. Noriega, T.A. Wartel, A. Bouckenooghe & B. Zambrano. (2018) Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America. Clinical Microbiology and Infection 24:7, pages 755-763.
Crossref
Crossref
Sarah Sebastian & Teresa Lambe. (2018) Clinical Advances in Viral-Vectored Influenza Vaccines. Vaccines 6:2, pages 29.
Crossref
Crossref
Hossein Fahimi, Mahshid Mohammadipour, Hamed Haddad Kashani, Farshid Parvini & Majid Sadeghizadeh. (2018) Dengue viruses and promising envelope protein domain III-based vaccines. Applied Microbiology and Biotechnology 102:7, pages 2977-2996.
Crossref
Crossref
Félix A Rey, Karin Stiasny, Marie‐Christine Vaney, Mariano Dellarole & Franz X Heinz. (2017) The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. EMBO reports 19:2, pages 206-224.
Crossref
Crossref